chemieunternehmen.com

Evotec SE and Alpine Immune Sciences today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-and-alpine-immune-sciences-expand-partnership-for-commercial-process-development-of-alpn-303-6201

Evotec SE will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-first-half-year-2022-results-on-11-august-2022-6199

Evotec SE announced today that after a successful call for proposals, University of Dundee has been awarded its first funding within the beLAB1407 BRIDGE initiative. beLAB1407 is a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb, aiming to accelerate translational research from the UK’s academic life science ecosystem.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-translational-bridge-belab1407-awards-project-from-dundee-university-6197

Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-boehringer-ingelheim-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance-6195